Siemens AG has signed an agreement to acquire Dotmatics, a provider of Life Sciences R&D software, for $5.1 billion from Insight Partners. This acquisition expands Siemens’ digital capabilities, bringing its Digital Twin technology and AI-powered software into the growing Life Sciences sector. Dotmatics offers a highly profitable portfolio of scientific applications and multi-modal data management tools that help accelerate innovation in drug development. Siemens plans to integrate Dotmatics into its Siemens Xcelerator platform, further strengthening its industrial software portfolio. Financing for the acquisition will primarily come from the sale of Siemens’ shares in listed companies, including Siemens Healthineers.
Ralf P. Thomas, CFO of Siemens AG, stated, “The acquisition of Dotmatics drives strong revenue synergies and is highly profitable and cash-generative. Financing will be provided primarily through the sale of shares in listed companies, including Siemens Healthineers.” The acquisition supports Siemens’ strategy to grow in industries with high R&D spending, like Life Sciences, and is expected to deliver significant revenue synergies. Siemens aims to combine its industrial expertise with Dotmatics’ R&D platforms to create a connected digital framework from research to production, strengthening its presence in this fast-growing market.
